Opus Genetics IRD Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's effective income tax rate reconciliation nondeductible expense share based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's effective income tax rate reconciliation nondeductible expense share based compensation cost?
- Opus Genetics (IRD) reported effective income tax rate reconciliation nondeductible expense share based compensation cost of -0.5% in Q4 2025.
- How has Opus Genetics's effective income tax rate reconciliation nondeductible expense share based compensation cost changed year-over-year?
- Opus Genetics's effective income tax rate reconciliation nondeductible expense share based compensation cost increased by 37.5% year-over-year, from -0.8% to -0.5%.
- What does effective income tax rate reconciliation nondeductible expense share based compensation cost mean?
- Reflects the percentage impact of non-deductible share-based compensation expenses on the effective tax rate. It provides insight into how equity compensation structures affect the company's overall tax burden.